A single genetics acronym can carry a great deal of hope, pressure, and uncertainty when you are planning IVF. Understanding PGT-A versus PGT-M testing begins with one key point: these tests answer different questions about an embryo. Neither is automatically the better choice. The right approach depends on your medical history, age, family genetics, and the reason you are pursuing fertility treatment.
Both tests are performed as part of IVF and involve examining a small sample of cells from an embryo before transfer. They can help your fertility specialist make more informed decisions, but they cannot promise implantation, a healthy pregnancy, or a live birth. Thoughtful counseling is essential so that the testing plan supports your family-building goals.
What Preimplantation Genetic Testing Involves
Preimplantation genetic testing, often called PGT, is performed after eggs are retrieved, fertilized in the laboratory, and grown to the blastocyst stage, typically around day 5 or 6 of development. At this stage, an embryologist carefully removes a few cells from the outer layer of the embryo. These cells are expected to form the placenta, rather than the fetus itself.
The embryo is usually frozen while the genetic laboratory analyzes the sample. Once results are available, your specialist can discuss which embryos may be suitable for a future frozen embryo transfer.
PGT is not a single test. PGT-A looks at chromosome number, while PGT-M looks for a specific inherited genetic condition. In some circumstances, both tests may be considered together.
PGT-A: Looking at Chromosome Number
PGT-A stands for preimplantation genetic testing for aneuploidy. Aneuploidy means that an embryo has an extra or missing chromosome. Most people have 46 chromosomes arranged in 23 pairs. An embryo with the expected number is described as euploid; one with an abnormal number is described as aneuploid.
Chromosome abnormalities are a common reason embryos do not implant, pregnancies miscarry, or babies are born with certain chromosome conditions. The chance of aneuploid embryos tends to rise with maternal age, particularly from the late 30s onward, though it can occur at any reproductive age.
PGT-A may be discussed for patients who have had recurrent pregnancy loss, repeated unsuccessful embryo transfers, a history of pregnancies affected by chromosome abnormalities, or IVF at an age where aneuploidy is more likely. It may also help when several embryos are available and a patient wants information that may guide transfer order.
However, PGT-A is not right for every IVF cycle. If only a small number of embryos are expected, testing may not change the treatment plan and could leave no embryo categorized as suitable for transfer. Your specialist will weigh possible benefits against the number of eggs or embryos anticipated, your reproductive history, and your priorities around timing and cost.
What PGT-A cannot tell you
PGT-A does not test for every possible genetic condition. It does not identify most single-gene disorders, such as thalassemia, cystic fibrosis, or a known familial gene mutation. It also cannot measure all factors involved in embryo development, implantation, placental health, or a child’s long-term health.
Occasionally, results may show mosaicism, meaning the sampled cells contain a mix of chromosome patterns. Mosaic results can be complex and should be reviewed carefully with an experienced fertility specialist and, when appropriate, a genetic counselor. A biopsy is a sample, not a complete picture of every cell in an embryo.
PGT-M: Testing for a Known Familial Condition
PGT-M stands for preimplantation genetic testing for monogenic or single-gene conditions. It is designed for individuals or couples who know they carry, or may carry, a specific genetic variant that could be passed to their children.
Unlike PGT-A, PGT-M is targeted. The laboratory is not broadly looking for extra or missing chromosomes. It is looking for the particular condition that has been identified in a family, such as alpha or beta thalassemia, spinal muscular atrophy, Huntington disease, or certain inherited cancer predisposition syndromes. It may also be relevant for X-linked conditions, where the genetic risk can differ depending on the embryo’s sex chromosomes.
Before treatment begins, the genetics laboratory generally needs time to develop a customized test for the family. This process may require genetic reports from the intended parents and sometimes samples from relatives, depending on the condition and laboratory method. Starting these conversations early can prevent unnecessary delays once IVF is underway.
PGT-M can be especially meaningful for families who have experienced the impact of a serious inherited condition firsthand. For some, it offers a way to reduce the likelihood of passing on a known disorder while pursuing pregnancy with their own eggs and sperm. The decision remains deeply personal, and supportive, nonjudgmental counseling matters.
When PGT-M and PGT-A may be used together
An embryo can be unaffected by a known single-gene condition but still have a chromosome-number abnormality. For this reason, some patients using PGT-M also consider PGT-A. Combining the tests may provide broader information, particularly when maternal age or reproductive history suggests a higher possibility of aneuploidy.
That said, adding PGT-A is not always necessary or preferred. It can increase testing complexity and cost, and it may not offer the same value for every patient. Your care team should explain what each result would mean for your available embryos before you decide.
The Practical Difference Between PGT-A Versus PGT-M Testing
The clearest distinction is the question each test asks. PGT-A asks whether the embryo appears to have the expected number of chromosomes. PGT-M asks whether the embryo has inherited a specific genetic condition already known in the family.
A couple with no known inherited disorder but recurrent miscarriages may be more likely to discuss PGT-A. A couple in which one partner carries beta thalassemia may need PGT-M, even if they are young and have no history of infertility. A person can also be a carrier of a condition without symptoms, which is why preconception carrier screening and genetic counseling can be valuable before pregnancy or IVF.
Neither test replaces a full fertility assessment. Egg quality, sperm factors, uterine health, embryo development, hormone patterns, and underlying medical conditions can all affect the path to pregnancy. Genetic testing is one part of a personalized IVF plan, not a standalone solution.
Questions to Discuss Before You Decide
A consultation should give you room to consider both the medical facts and what feels manageable for your family. Ask why a particular test is being recommended in your case, how long the process may take, what outcomes are possible if no embryos are suitable for transfer, and whether results could be uncertain.
It is also reasonable to ask about the number of embryos expected, the chance that testing will change your treatment decisions, and the costs involved. If PGT-M is being considered, confirm whether a customized laboratory setup is needed and what genetic records should be prepared.
Even after PGT, prenatal screening and, in some cases, diagnostic testing during pregnancy may still be recommended. PGT reduces certain risks; it does not eliminate every possibility of a genetic or developmental concern.
A Decision Grounded in Your Story
Choosing genetic testing can feel like another high-stakes decision in an already demanding fertility journey. At IVcare Fertility, the goal is not to apply the same test to every patient, but to understand the medical and personal reasons behind your choices. With clear genetic guidance and compassionate fertility care, you can move forward with a plan that honors both science and the new beginning you hope to create.
